Ibrutinib + Venetoclax in Untreated WM

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom\'s macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: * Venetoclax * ibrutinib
Epistemonikos ID: d35b0a4143b77e5f348e4d1d93948ea832e132e4
First added on: May 07, 2024